Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luminespib - Vernalis

Drug Profile

Luminespib - Vernalis

Alternative Names: AUY-922; NVP-AUY-922; VER-52296

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis; Royal Marsden NHS Foundation Trust; Sarah Cannon Research Institute; SCRI Development Innovations; The Institute of Cancer Research; University of Texas M. D. Anderson Cancer Center; University of Toronto; Vernalis
  • Class Amides; Antineoplastics; Isoxazoles; Morpholines; Resorcinols; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Head and neck cancer
  • Suspended Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Lymphoma; Multiple myeloma; Myeloproliferative disorders; Non-small cell lung cancer; Solid tumours
  • Discontinued Pancreatic cancer

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 24 Jun 2018 Biomarkers information updated
  • 25 Apr 2017 Preclinical trials in Head and neck cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top